SUMMIT (dpa-AFX) - Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corp. (CELG), said the latest research on Otezla (apremilast), the company's oral, selective inhibitor of phosphodiesterase 4 or PDE4, will be presented at the 24th European Academy of Dermatology and Venereology Congress in Copenhagen, Denmark, October 7-11.
Nine abstracts - one oral presentation and eight e-posters - evaluating the use of OTEZLA in plaque psoriasis and pre-clinical data in atopic dermatitis will be presented at the meeting.
Data to be presented include pre-specified analyses of the LIBERATE study assessing the impact of oral OTEZLA 30 mg twice daily or weekly subcutaneous etanercept 50 mg, each compared with placebo.
Changes in patient-reported pruritus (itching) and health-related quality of life through 32 weeks of treatment in patients with moderate to severe plaque psoriasis are considered.
Efficacy and safety results from the LIBERATE study were previously presented at this year's Annual Meeting of the American Academy of Dermatology in San Francisco, California. LIBERATE was not designed or powered to directly compare OTEZLA to etanercept.
Copyright RTT News/dpa-AFX